Taxotere Approved in Canada for Advanced Breast Cancer and NSCLC
COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) has received approval from the Canadian Health Protection Branch for use as second-line treatment of advanced breast and non-small-cell lung cancer (NSCLC). The new drug submission was based on clinical trials involving more than 800 patients worldwide.
COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel)has received approval from the Canadian Health Protection Branchfor use as second-line treatment of advanced breast and non-small-celllung cancer (NSCLC). The new drug submission was based on clinicaltrials involving more than 800 patients worldwide.
Articles in this issue
New Probe Detects Fusion of bcr/abl
Avon's Breast Cancer Crusade to Offer 'Pink Ribbon' Pens
Take a Behind the Scenes Look at ODAC
Michigan Cancer System Named for Woman
Panel Favors Approval of Gemzar for Use In Patients With Late Stage Pancreatic Cancer
High-Dose Chemo Patients to Get Stem Cells With the MDR-1 Gene
Report on Minority Health Finds Few Black Oncologists
Where Are We Going and What Questions Do We Need to Ask?
Phase I Trial of Circadian Patterned Infusion of Continuous IL-2 Opens
Hodgkin's Disease Patients Sought for Trial of MoAb
New Health Care Insurance Reform Legislation Introduced in the Senate
FDA Approves Phase II Trials of Agouron's HIV Protease Inhibitor
House committee Recommends Budget Increases for NIH, NCI
Two New Appointees at the NCI
Chemo Plus Transplant Promising For Advanced Hepatocellular Cancer
Recent Videos
